SUNPHARMA's weekly performance was disappointing, with a return of -0.92% and a Sharpe Ratio of -0.17, indicating poor risk-adjusted returns. The stock's volatility was high at 27.39%, making it a risky investment this week. Compared to its peers, SUNPHARMA underperformed DRREDDY and DIVISLAB, but outperformed HINDUNILVR. Overall, the stock's high volatility and negative returns make it a cautious investment opportunity.

[Volatility: 27.39%]